Sökning: (WFRF:(Kuteeva E.)) > Membranous expressi...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05152naa a2200553 4500 | |
001 | oai:DiVA.org:kth-136897 | |
003 | SwePub | |
008 | 131209s2013 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:59451232-9eb4-425f-8401-661993b0f9fa | |
009 | oai:DiVA.org:uu-199936 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-1368972 URI |
024 | 7 | a https://doi.org/10.1038/bjc.2013.2152 DOI |
024 | 7 | a https://lup.lub.lu.se/record/38047952 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1999362 URI |
040 | a (SwePub)kthd (SwePub)lud (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Boman, Karolinau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-kba |
245 | 1 0 | a Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer |
264 | c 2013-05-07 | |
264 | 1 | b Springer Science and Business Media LLC,c 2013 |
338 | a print2 rdacarrier | |
500 | a QC 20131213 | |
520 | a Background: Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer. Methods: Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n = 100 (Cohort I) and n = 343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed. Results: Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR = 2.25 in Cohort I and 3.10 in Cohort II, adjusted HR = 2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR = 4.36, adjusted HR = 2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR = 6.19, adjusted HR = 4.60) and DSS (unadjusted HR = 8.34, adjusted HR = 7.16). Conclusion: Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a podocalyxin-like protein | |
653 | a urothelial bladder cancer | |
653 | a prognosis | |
700 | 1 | a Larsson, Anna Hu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-a_l |
700 | 1 | a Segersten, Ulrikau Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)ulriande |
700 | 1 | a Kuteeva, E.4 aut |
700 | 1 | a Johannesson, H.4 aut |
700 | 1 | a Nodin, Björnu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)immu-bnn |
700 | 1 | a Eberhard, Jakobu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-jeb |
700 | 1 | a Uhlén, Mathiasu KTH,Proteomik och nanobioteknologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:kth)u1dulvmw |
700 | 1 | a Malmström, Per-Unou Uppsala universitet,Urologkirurgi4 aut0 (Swepub:uu)perunoms |
700 | 1 | a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji |
710 | 2 | a Tumörmikromiljöb Sektion I4 org |
773 | 0 | t British Journal of Cancerd : Springer Science and Business Media LLCg 108:11, s. 2321-2328q 108:11<2321-2328x 0007-0920x 1532-1827 |
856 | 4 | u https://www.nature.com/articles/bjc2013215.pdf |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/23652315?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1038/bjc.2013.215y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-136897 |
856 | 4 8 | u https://doi.org/10.1038/bjc.2013.215 |
856 | 4 8 | u https://lup.lub.lu.se/record/3804795 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-199936 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.